XNCR News and Press, Xencor Inc. From 10/31/23

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will release third quarter 2023 financial results after the market closes on Tuesday, November 7, 2023. ...

2023-10-27 11:56:53 ET Summary Xencor is expected to release data from a phase 2 study in early 2024 targeting patients with mCRPC and gynecological cancers, which could generate shareholder value. The global metastatic castration-resistant prostate cancer treatment market is expe...

2023-10-26 10:50:51 ET More on Xencor Xencor: A Mid-Stage Clinical Company With Falling Losses Vir Biotech nabs $50M BARDA funding to discover antibody therapies Seeking Alpha’s Quant Rating on Xencor For further details see: Xencor finance chief t...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, announced that John J. Kuch, senior vice president and chief financial officer, plans to retire in March 2024, after a 23-year...

2023-10-20 23:02:01 ET Summary Xencor, Inc. is a biotech company focused on the development and commercialization of anticancer medications. They have successful partnerships and licensing agreements for approved molecules in hematologic cancers and blood disorders. Xencor's p...

2023-10-03 09:50:40 ET More on Vir, Xencor, etc. Vir Biotechnology: Strong Balance Sheet But Commercial Prospects Await Further Clarity Vir Biotechnology, Inc. 2023 Q2 - Results - Earnings Call Presentation Xencor, Inc. (XNCR) Q2 2023 Earnings Call Transcript ...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced three poster presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), being...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the appointment of Barbara J. Klencke, M.D., to its board of directors. Dr. Klencke has more than 20 years of ...

2023-08-06 03:20:23 ET Xencor, Inc. (XNCR) Q2 2023 Earnings Conference Call August 3, 2023, 04:30 PM ET Company Participants Charles Liles - Head of Corporate Communications & IR Bassil Dahiyat - Co-Founder and CEO Nancy Valente - Chief Development Officer ...

2023-08-03 16:32:45 ET Xencor press release ( NASDAQ: XNCR ): Q2 GAAP EPS of -$0.37 beats by $0.43 . Revenue of $45.5M (+50.8% Y/Y) beats by $19.22M . Cash, cash equivalents, receivables and marketable debt securities totaled $531.4 million as of June 30, 2023,...